Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889091 | 1.00 | TSHR (0.42) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL17746877 | 0.81 | TSHR (0.40) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL9242795 | 0.77 | TSHR (0.36) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL8733237 | 0.77 | TSHR (0.36) | TSHRTP53EGLN1EGLN3 | |
| SCHEMBL17186622 | 0.77 | — | — | |
| SCHEMBL4791763 | 0.77 | — | — | |
| SCHEMBL408424 | 0.77 | — | — | |
| SCHEMBL239930 | 0.77 | — | — | |
| SCHEMBL899316 | 0.74 | TSHR (0.44) | TSHRTP53EGLN1EGLN3LMNA | |
| Hydrochloric Acid SCHEMBL9396950 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049464-B2 | Process for producing of an aminoalkylsulfonic acid and a method of salt exchange for a salt thereof | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2006-05-23 | — | — | US | disclosed |
| US-20050261370-A1 | Process for producing of an aminoalkylsulfonic acid and a method of salt exchange for a salt thereof | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1548002-A1 | PROCESS FOR PRODUCING AMINOALKYLSULFONIC ACID AND METHOD OF SALT EXCHANGE FOR SALT THEREOF | Wako Pure Chemical Industries, Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261370-A1 | Process for producing of an aminoalkylsulfonic acid and a method of salt exchange for a salt thereof | ARSA, ADSL, ASS1 | TSHR 2671/4885TP53 3930/4885EGLN1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.